(NASDAQ: BIOA) Bioage Labs's forecast annual earnings growth rate of N/A is not forecast to beat the US Drug Manufacturers - Specialty & Generic industry's average forecast earnings growth rate of 14.57%, and while it is not forecast to beat the US market's average forecast earnings growth rate of 34.38%.
Bioage Labs's earnings in 2026 is -$89,930,000.On average, 12 Wall Street analysts forecast BIOA's earnings for 2026 to be -$115,950,511, with the lowest BIOA earnings forecast at -$132,433,585, and the highest BIOA earnings forecast at -$98,951,786. On average, 12 Wall Street analysts forecast BIOA's earnings for 2027 to be -$92,626,162, with the lowest BIOA earnings forecast at -$131,562,312, and the highest BIOA earnings forecast at $53,676,676.
In 2028, BIOA is forecast to generate -$124,987,752 in earnings, with the lowest earnings forecast at -$145,676,055 and the highest earnings forecast at -$98,485,032.